Aspiriant LLC’s Schwab US Broad Market ETF SCHB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.33M Buy
80,573
+858
+1% +$24K 0.06% 103
2026
Q1
$2M Hold
79,715
0.06% 109
2025
Q4
$2.09M Buy
79,715
+1,875
+2% +$48.8K 0.06% 108
2025
Q3
$2M Hold
77,840
0.06% 102
2025
Q2
$1.85M Hold
77,840
0.06% 106
2025
Q1
$1.68M Buy
77,840
+3,596
+5% +$81.8K 0.06% 106
2024
Q4
$1.69M Sell
74,244
-3,909
-5% -$89.3K 0.06% 105
2024
Q3
$1.73M Buy
78,153
+3,909
+5% +$83.5K 0.07% 104
2024
Q2
$1.56M Sell
74,244
-108
-0.1% -$2.19K 0.06% 103
2024
Q1
$1.51M Hold
74,352
0.06% 112
2023
Q4
$1.38M Hold
74,352
0.06% 117
2023
Q3
$1.24M Hold
74,352
0.06% 118
2023
Q2
$1.28M Buy
74,352
+1,584
+2% +$25.8K 0.06% 113
2023
Q1
$1.16M Hold
72,768
0.06% 122
2022
Q4
$1.09M Sell
72,768
-3,414
-4% -$51.3K 0.06% 124
2022
Q3
$1.07M Buy
76,182
+1,740
+2% +$27.1K 0.05% 115
2022
Q2
$1.1M Buy
74,442
+48
+0.1% +$770 0.05% 115
2022
Q1
$1.32M Buy
74,394
+912
+1% +$16K 0.07% 114
2021
Q4
$1.38M Buy
+73,482
New +$1.35M 0.07% 111

Other funds holding SCHB

Aspiriant LLC's SCHB Position: Q2 2026 in Review

Aspiriant LLC increased its Schwab US Broad Market ETF (SCHB) stake by 1.1% in Q2 2026, buying an estimated $24K and bringing the position to 80,573 shares worth $2.33M. The position accounts for 0.06% of the portfolio, ranked #103.

Aspiriant LLC first reported a position in SCHB in Q4 2021 and has held it in 19 quarters since. 1,391 funds tracked by Wall St. Rank hold SCHB as of Q2 2026.

  • Aspiriant LLC held 80,573 shares of Schwab US Broad Market ETF worth $2.33M as of Q2 2026.
  • Aspiriant LLC bought 858 Schwab US Broad Market ETF shares in Q2 2026, an estimated $24K.
  • Schwab US Broad Market ETF made up 0.06% of Aspiriant LLC's portfolio in Q2 2026, its #103 holding.
  • Aspiriant LLC first reported a position in Schwab US Broad Market ETF in Q4 2021 and has held it in 19 quarters since.
  • 1,391 funds tracked by Wall St. Rank held Schwab US Broad Market ETF as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.